Here are 1-3 brief analogies for TransMedics:

• It's like GE HealthCare for donor organs, providing advanced, life-sustaining systems specifically for organs outside the body.
• Think of it as the Intuitive Surgical of organ transplantation, developing high-tech systems that transform how organs are preserved and utilized.

• Organ Care System (OCS): A portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body.
• OCS LUNG: A component of the OCS specifically designed for the preservation of standard criteria donor lungs for double-lung transplantation.
• OCS Heart: A technology within the OCS used for extracorporeal perfusion and preservation of donor hearts.
• OCS Liver: A part of the OCS utilized for the preservation of donor livers.

TransMedics (TMDX) sells specialized medical technology, the Organ Care System (OCS), which is used in the complex process of organ transplantation. Therefore, its customers are not individuals but rather medical institutions.

The major category of customers that TransMedics serves is:

• Hospitals and Organ Transplant Centers: These are medical institutions, often large academic medical centers or specialized hospitals, that operate organ transplant programs for heart, lung, and liver recipients. They acquire TransMedics' OCS devices to improve the preservation, assessment, and utilization of donor organs, thereby aiming to expand the donor pool and enhance the success rates of transplantation procedures for end-stage organ failure patients.

Waleed Hassanein, M.D. TransMedics Founder, President and CEO

Dr. Waleed Hassanein founded TransMedics in 1998 with the aim of revolutionizing organ transplant therapy. His pioneering clinical research led to the development of a new field of living organ preservation for transplantation. He earned his M.D. from Georgetown University School of Medicine and completed a cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women's Hospital. In 1998, his research on ex-vivo heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery. Dr. Hassanein has been recognized as a top Global Thinker in Healthcare and received the Tribeca Disruptive Innovator Award in 2018. He has served as a director of the company since August 1998.

Gerardo Hernandez Omana Chief Financial Officer and Treasurer

Gerardo Hernandez Omana was appointed Chief Financial Officer and Treasurer of TransMedics, effective December 2, 2024. He brings over 25 years of experience in finance across the healthcare and consumer packaged goods sectors. Before joining TransMedics, he served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals. Prior to that, he spent nearly a decade at Shire, where he led corporate FP&A and was instrumental in the integration efforts following Shire's $62 billion acquisition by Takeda. Mr. Hernandez began his career at Unilever. He holds a Bachelor of Science degree in Finance from the University of Wisconsin–La Crosse and an MBA in Strategy & Economics from Fundação Getulio Vargas, São Paulo.

Tamer Khayal, M.D. Chief Commercial Officer

Dr. Tamer Khayal joined TransMedics in 2001 and has since taken on increasing responsibilities, culminating in his appointment as Chief Commercial Officer in January 2018. From 2007 to 2018, he served as Chief Medical Officer, overseeing global initiatives for clinical evidence, reimbursement, and integration programs to support the approval and adoption of the Organ Care System (OCS) technology. Before joining TransMedics, Dr. Khayal was the Director of Medical Affairs for Zentiva Middle East, a pharmaceutical company. He received his M.D. degree from Cairo University School of Medicine.

Anil Ranganath Senior Vice President, General Counsel and Corporate Secretary

Nicholas Corcoran Senior Vice President of Supply Chain and Operations

Here are the key risks to TransMedics (TMDX) business:

1. Regulatory and Legal Scrutiny: TransMedics faces significant risks due to ongoing legal actions and allegations of fraudulent practices. A class-action lawsuit has been filed, accusing the company of using kickbacks, engaging in fraudulent overbilling, employing coercive tactics to boost business, and concealing safety issues. There are also allegations of steering rejected organs to certain users and inadequate training of technicians managing organs on their OCS devices. These accusations expose TransMedics to heightened regulatory risk, potential legal liabilities, and reputational damage.
2. Competition and Market Dynamics: The company operates in a competitive environment with other players developing organ preservation technologies, such as XVIVO Perfusion, OrganOx, and Paragonix Technologies. While TransMedics currently holds a strong market position, particularly in warm perfusion organ transplants in the United States, there is a risk of market saturation and slowing growth as the U.S. market matures. The emergence of alternative organ preservation protocols, such as Normothermic Regional Perfusion (NRP), could also limit the total addressable market for TransMedics' Organ Care System (OCS). Furthermore, international expansion may be challenging due to differing reimbursement models and regulatory hurdles, and increased competition in specific organ markets (e.g., liver transplants) could pressure market share and pricing.
3. Operational and Supply Chain Challenges: TransMedics faces operational risks related to scaling its manufacturing and sterilization capabilities to meet increasing demand for its products. The company's reliance on single-source suppliers for key components also poses a vulnerability. Additionally, its National OCS Program (NOP) involves a complex logistics infrastructure, including an owned aviation fleet, which introduces risks such as potential disruptions in aviation services, fluctuating fuel costs, maintenance issues, and the company's relatively limited experience in operating aircraft.

TransMedics (TMDX) offers its Organ Care System (OCS) for the preservation and assessment of donor organs. The addressable markets for its main products are as follows:

• OCS Liver: The global Organ Care System market for liver is estimated to reach approximately $40.5 million by the end of 2026. In North America, the OCS market size for liver is projected to reach $17.4 million by 2026.

• OCS Lung: The global Organ Care System market for lung is forecasted to generate approximately $5.6 million in revenue by 2026. For North America, the OCS lung market size is expected to grow to approximately $1.2 million by 2026.

• OCS Heart: Specific addressable market size for the OCS Heart product was not explicitly quantified in the search results. However, TransMedics is actively working to expand the addressable heart transplant market through its OCS Heart technology and clinical trials.

TransMedics Group, Inc. (TMDX) is expected to drive future revenue growth over the next two to three years through several key initiatives and expansions:

1. Increased Utilization of Organ Care System (OCS) in the U.S. The company anticipates continued revenue growth from the expanded adoption and utilization of its Organ Care System (OCS) for existing indications, particularly in liver and heart transplants, within its National OCS Program (NOP) in the United States. TransMedics reported a significant increase in U.S. OCS cases, reaching 5,139 in 2025, up 38% year-over-year.
2. Expansion of Transplant Logistics Infrastructure. Revenue growth is also expected from the ongoing expansion and heightened utilization of TransMedics' proprietary transplant logistics services, including its aviation fleet. The company continues to invest in and leverage its robust logistics capabilities to support the National OCS Program, enhancing its ability to cover NOP missions requiring air transport.
3. International Market Expansion. TransMedics is focused on expanding its NOP model into international markets. Active launches are underway in European markets, with Italy specifically highlighted for the first half of 2026. This international expansion is projected to significantly increase the company's total addressable market and contribute to future revenue growth.
4. Introduction of New OCS Programs and Indications. The company is investing in and advancing its clinical pipeline to develop and launch new OCS programs and expand existing indications. This includes progress with programs such as OCS Kidney, for which the company aims to have the platform ready for FDA trials by early 2027, as well as the OCS ENHANCE Heart and DENOVO Lung programs. These new offerings are expected to broaden the clinical adoption of OCS technology and serve as significant revenue catalysts.

Share Issuance

• TransMedics completed an underwritten public offering of 3,250,000 shares of its common stock at $40.00 per share in August 2022, generating gross proceeds of approximately $130 million.

Capital Expenditures

• TransMedics reported capital expenditures of approximately $151.85 million in fiscal year 2023 and $129.74 million in fiscal year 2024.
• For the trailing twelve months ending September 30, 2025, capital expenditures were approximately $57.34 million.
• The primary focus of capital expenditures has been on ongoing upgrades to expand manufacturing, enhancing infrastructure for long-term scalability, and the expansion of its owned and operated aircraft fleet for organ transport, which reached 22 aircraft as of December 31, 2025. Investments also support research, clinical programs, and commercial infrastructure.